N-[(2S)-1-[[(2S,5R)-5-benzyl-1-methoxy-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]amino]-3-methoxy-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(2S)-1-[[(2S,5R)-5-benzyl-1-methoxy-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]amino]-3-methoxy-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
• 化学式: C₂₆H₃₃N₃O₇S
• 分子量: 531.6
• InChiKey: JKBVLAVGZWDSGH-WWMMDOJLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  37
• 可旋转键数：
  15
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  165
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• Method for the Treatment of Neuropathies Associated with Charcot-Marie-Tooth 1A (CMT1A) Disease
  申请人：National Institutes of Health, US Dept of Health and Human Services

  公开号：US20140080787A1

  公开（公告）日：2014-03-20

  The present invention relates to compositions and methods for the treatment, prevention, and diagnosis of neuropathies due to PMP22 mis-expression in a subject having Charcot-Marie-Tooth disease, especially Charcot-Marie-Tooth 1A disease. The present invention incorporates the use of small molecule proteasome inhibitors such as, but not limited to, Bortezomib to inhibit or reduce the overexpression of the PMP2 gene.